Drug
Piclidenoson
Piclidenoson is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
completed133%
not_yet_recruiting267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_2
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
NCT07410455
not_yet_recruitingphase_3
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
NCT06643260
completedphase_2
Piclidenoson for Treatment of COVID-19
NCT04333472
Clinical Trials (3)
Showing 3 of 3 trials
NCT07410455Phase 2
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
NCT06643260Phase 3
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
NCT04333472Phase 2
Piclidenoson for Treatment of COVID-19
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3